Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Kalvista Pharmaceuticals, Ltd.

Clinical trials sponsored by Kalvista Pharmaceuticals, Ltd., explained in plain language.

KalVista Pharmaceuticals KALV NASDAQ

A pharmaceutical company developing oral therapies for hereditary angioedema and other diseases.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Not yet recruiting 1 Completed 4 Terminated 1

Could a simple pill shield HAE patients from Procedure-Triggered attacks?

Disease control Not yet recruiting

This trial tests whether the drug sebetralstat can prevent swelling attacks in people with hereditary angioedema (HAE) when taken before a medical procedure. Participants aged 12 and older with HAE type I or II will take sebetralstat just before their scheduled procedure. The mai…

Phase: PHASE4 • Sponsor: KalVista Pharmaceuticals, Ltd. • Aim: Disease control

Last updated Jul 18, 2026 00:00 UTC